Korro Bio (KRRO) Receivables - Net (2018 - 2025)

Korro Bio (KRRO) posted Receivables - Net of $969000.0 for Q4 2025, up 18.17% on a QoQ basis from $820000.0 in Q3 2025, and down 42.87% year-over-year from $1.7 million in Q4 2024.

Korro Bio (KRRO) Receivables - Net (2018 - 2025) Analysis & Trends

Korro Bio's Receivables - Net history runs 5 years deep, the most recent figure standing at $969000.0 for Q4 2025.

  • Quarterly Receivables - Net fell 42.87% year-over-year to $969000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $969000.0 (down 42.87% YoY) and the FY2025 annual result came in at $1.0 million, down 41.18% from the prior year.
  • Receivables - Net was $969000.0 for Q4 2025 at Korro Bio, up from $820000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $10.0 million in Q3 2024 and bottomed at $820000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Korro Bio 123.70 Mn 9.73 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 969,000.00
Dec 31, 2025 969,000.00
Sep 30, 2025 820,000.00
Sep 30, 2025 820,000.00
Jun 30, 2025 1.10 Mn
Jun 30, 2025 1.10 Mn
Mar 31, 2025 1.92 Mn
Mar 31, 2025 1.92 Mn
Dec 31, 2024 1.70 Mn
Dec 31, 2024 1.70 Mn
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn
Mar 31, 2020 246,000.00
Mar 31, 2020 246,000.00
Dec 31, 2019 805,000.00
Dec 31, 2019 805,000.00
Sep 30, 2019 408,000.00
Sep 30, 2019 408,000.00
Dec 31, 2018 161,000.00
Dec 31, 2018 161,000.00